Financial reports
10-K
2023 FY
Annual report
18 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
25 Apr 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
29 Mar 22
Current reports
8-K
Material Modifications to Rights of Security Holders
20 Mar 24
8-K
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
18 Mar 24
8-K
Regulation FD Disclosure
8 Feb 24
8-K
In the Court of Chancery of the State of Delaware
6 Feb 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Dec 23
8-K/A
Departure of Directors or Certain Officers
4 Dec 23
8-K
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
9 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
8-K
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
10 Aug 23
Registration and prospectus
S-3
Shelf registration
21 Mar 24
424B3
Prospectus supplement
20 Mar 24
S-8
Registration of securities for employees
18 Mar 24
S-3
Shelf registration
4 Mar 24
D
$127.80 mm in equity / options, sold $127.80 mm, 20 investors
21 Feb 24
424B5
Prospectus supplement for primary offering
11 May 23
S-3
Shelf registration
25 Apr 23
S-8
Registration of securities for employees
30 Mar 23
S-8
Registration of securities for employees
11 Aug 22
S-8
Registration of securities for employees
29 Mar 22
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 23
DEF 14A
Definitive proxy
25 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 22
DEF 14A
Definitive proxy
26 Apr 22
DFAN14A
Additional proxy materials by non-management
12 May 21
DFAN14A
Additional proxy materials by non-management
11 May 21
DEFA14A
Additional proxy soliciting materials
10 May 21
DFAN14A
Additional proxy materials by non-management
10 May 21
DFAN14A
Additional proxy materials by non-management
6 May 21
Other
EFFECT
Notice of effectiveness
1 Apr 24
EFFECT
Notice of effectiveness
27 Mar 24
UPLOAD
Letter from SEC
25 Jan 24
CORRESP
Correspondence with SEC
17 Jan 24
UPLOAD
Letter from SEC
18 Dec 23
EFFECT
Notice of effectiveness
3 May 23
UPLOAD
Letter from SEC
1 May 23
CORRESP
Correspondence with SEC
28 Apr 23
UPLOAD
Letter from SEC
16 Apr 21
UPLOAD
Letter from SEC
8 Apr 21
Ownership
4
Setareh Seyedkazemi
12 Mar 24
4
Peter Soparkar
12 Mar 24
4
Laurent Fischer
12 Mar 24
SC 13G
Logos Global Management LP
22 Feb 24
SC 13G
TCG Crossover GP II, LLC
15 Feb 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
4
Setareh Seyedkazemi
14 Feb 24
4
Laurent Fischer
14 Feb 24
SC 13G
Vivo Opportunity Fund Holdings, L.P.
14 Feb 24
4
Linda M Rubinstein
14 Feb 24